Author Archives: Diogo Pinto

Axovant Enters Global Licensing Deal with Benitec for Investigational AXO-AAV-OPMD Program to Treat OPMD

Benitec Biopharma recently granted Axovant Sciences worldwide rights to its investigational AXO-AAV-OPMD gene therapy program for the treatment of oculopharyngeal muscular dystrophy (OPMD) under a global licensing agreement. AXO-AAV-OPMD is currently in preclinical development, and Axovant plans to launch a placebo-controlled trial testing the therapy candidate for OPMD…